8-K: ADC Therapeutics Q1 2026 Results: Revenue Up, Net Loss Down

ADC Therapeutics reported first quarter 2026 net product revenue of $20.0 million, an increase from the prior year, while net loss narrowed to $33.0 million, driven by lower operating expenses.

Summary

• ADC Therapeutics reported first quarter 2026 net product revenue of $20.0 million, an increase from $17.4 million in the first quarter of 2025, primarily due to higher volume and pricing.
• Net loss for the quarter was $33.0 million ($0.21 per share), an improvement from a net loss of $38.6 million ($0.36 per share) in the first quarter of 2025.
• Adjusted net loss, a non-GAAP measure, was $19.7 million ($0.13 per share) for Q1 2026, compared to $24.0 million ($0.22 per share) in Q1 2025.
• Cash and cash equivalents stood at $231.0 million as of March 31, 2026, providing an expected cash runway at least into 2028.
• Topline data for the LOTIS-5 Phase 3 trial is anticipated in the second quarter of 2026, with full data for LOTIS-5 and LOTIS-7 expected by year-end.
• The company plans to submit a supplemental Biologics License Application (sBLA) to the FDA for ZYNLONTA in combination with rituximab before year-end if LOTIS-5 results are positive.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with revenue growth and reduced net loss being key positives, alongside clear upcoming clinical catalysts. However, the significant decrease in license revenue and ongoing substantial net loss temper the overall sentiment.

Positives

• Net product revenue increased to $20.0 million in Q1 2026 from $17.4 million in Q1 2025, driven by volume and price increases.
• Net loss decreased to $33.0 million in Q1 2026 from $38.6 million in Q1 2025.
• Adjusted net loss improved to $19.7 million in Q1 2026 from $23.9 million in Q1 2025.
• Cash and cash equivalents of $231.0 million provide a runway extending at least into 2028.
• Multiple near-term clinical catalysts are expected, including LOTIS-5 topline data in Q2 2026 and full LOTIS-5 and LOTIS-7 data by year-end.
• Potential for an sBLA submission for ZYNLONTA in combination therapy before year-end 2026.

Negatives

• License revenues and royalties decreased significantly to $0.8 million in Q1 2026 from $5.6 million in Q1 2025, due to a prior year milestone payment.
• Cost of product sales increased to $3.6 million in Q1 2026 from $2.1 million in Q1 2025, attributed to a shift in personnel focus to commercial manufacturing.
• Total shareholders' deficit was $(216.4) million as of March 31, 2026, compared to $(185.8) million as of December 31, 2025.

Risks

• The timing and outcome of the LOTIS-5 Phase 3 trial topline data release and subsequent sBLA submission and review by the FDA.
• Uncertainty regarding the full LOTIS-7 trial results and the potential regulatory and commercial pathways.
• The ability of partners to commercialize ZYNLONTA in foreign markets and obtain regulatory approvals.
• The significant cash required to service indebtedness, including facilities with HealthCare Royalty Management, Blue Owl, and Oaktree.
• Potential impact of international trade policies, tariffs, sanctions, and trade barriers on business operations and financial condition.
• The Company's ability to obtain necessary financial and other resources for its ongoing research, development, clinical, and commercial activities.

Future Outlook

The company anticipates multiple near-term catalysts, including topline results from the LOTIS-5 Phase 3 trial in the second quarter of 2026, with full data for LOTIS-5 and LOTIS-7 expected by year-end. If LOTIS-5 results are positive, a supplemental Biologics License Application (sBLA) to the FDA is planned before year-end 2026, with potential compendia inclusion in the first half of 2027 and confirmatory approval thereafter. Investigator-initiated trials in indolent lymphomas are also progressing, with data expected between late 2026 and mid-2027.

Management Comments

• "During the first quarter, we continued to build momentum across our ZYNLONTA program," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics.
• "Looking ahead, we have multiple near-term catalysts, including topline results from LOTIS-5 anticipated in the second quarter, full results expected from both LOTIS-5 and LOTIS-7 by year-end, as well as additional updates from the investigator-initiated studies in indolent lymphomas ahead."
• "We believe that we are well-positioned to expand ZYNLONTA's role across B-cell malignancies, accelerating our expected growth trajectory starting in 2027."

Industry Context

StockSavvy.ai notes that ADC Therapeutics' focus on ZYNLONTA in B-cell malignancies aligns with the broader industry trend of developing targeted therapies for hematological cancers. The company's progress in Phase 3 trials and potential sBLA submission highlight the competitive landscape for treatments in relapsed or refractory diffuse large B-cell lymphoma.

Comparison to Industry Standards

• The reported net product revenue of $20.0 million for Q1 2026 shows a year-over-year increase, indicating potential market penetration for ZYNLONTA, though direct comparisons to specific competitors' quarterly revenues are not provided in the filing.
• The net loss of $33.0 million and adjusted net loss of $19.7 million are typical for a commercial-stage biotechnology company investing heavily in clinical development and commercialization, but specific industry benchmarks for companies at this stage with similar product portfolios are not detailed.
• The cash runway extending into 2028 is a critical metric for biotech companies; while positive, its adequacy depends on future funding needs and R&D pipeline progression compared to peers.

Stakeholder Impact

• Shareholders: Potential positive impact from progress in clinical trials and expected revenue growth, balanced by ongoing net losses and the company's substantial debt.
• Employees: Continued investment in R&D and commercialization suggests ongoing employment opportunities, though personnel cost shifts are noted.
• Creditors: The company's cash position and runway provide some assurance, but the significant debt load remains a factor.
• Partners: Progress in clinical development and regulatory submissions for ZYNLONTA is crucial for partners involved in its commercialization.

Next Steps

• Announce topline results from the LOTIS-5 Phase 3 trial in the second quarter of 2026.
• Complete enrollment in the LOTIS-7 Phase 1b trial at the selected dose in the first half of 2026.
• Share full data from LOTIS-7 trial at a medical meeting and through publication by the end of 2026.
• Submit a supplemental Biologics License Application (sBLA) to the FDA for ZYNLONTA in combination with rituximab before year-end 2026, if LOTIS-5 results are positive.
• Publish data from investigator-initiated trials in follicular lymphoma and marginal zone lymphoma between the end of 2026 and mid-2027.

Key Dates

Recommendation

The company shows positive revenue growth and improved net loss, with significant clinical catalysts on the horizon. However, the substantial net loss, ongoing R&D investment, and significant debt obligations warrant a cautious 'hold' rating until key trial results and regulatory outcomes are clearer.

Keywords

ADC Therapeutics, ZYNLONTA, loncastuximab tesirine-lpyl, antibody drug conjugate, B-cell malignancies, diffuse large B-cell lymphoma, clinical trials, financial results